Introduction
Treatment options for bacterial infections are threatened by the increase in anti-microbial resistance against conventional antibiotics. Therefore, alternative approaches are highly needed. Boosting endogenous defence mechanisms of the host is a potentially attractive strategy, with a low risk of inducing resistance in bacteria. In this context, cholesterol-lowering drugs, statins, have been investigated. Besides statins' impact on cholesterol metabolism, broad pleiotropic effects have been suggested [1] [2] [3] [4] . In addition to anti-inflammatory effects, statins have been described to promote the activity of immune cells such as macrophages [5, 6] , monocytes [7] and neutrophils [8] . The impact of statins on epithelial cells in this context is, however, less well covered [9, 10] .
Epithelial cells line all body surfaces and are thus exposed to the environment and the first cells in contact with invading pathogens. Besides providing a mechanical barrier, epithelial cells are equipped with innate pattern recognition receptors and defence molecules to prevent bacterial infection. Anti-microbial peptides constitute a class of such defence effectors and are expressed by virtually all epithelial surfaces of the body [11] . These small, cationic peptides exert immediate anti-bacterial effects against a wide variety of microorganisms. Although reduced sensitivity to anti-microbial peptides can be detected among some highly virulent bacterial isolates [12] , widespread acquisition of high-level resistance has not developed during the long time-span that bacteria have been exposed to these molecules [11] . The presence of many different classes of anti-microbial peptides at the site of infection most probably contributes to the efficacy of these endogenous antibiotics [11, 13] .
A linkage between statins and the expression of the anti-microbial peptide LL-37/hCAP-18 has previously been described in airway epithelial cells [10] . In addition, pravastatin has been suggested to reduce the recurrence of urinary tract infections [14] , but clinical data on the overall effect of statins on urinary tract infections are limited and inconsistent [15] [16] [17] .
Here we investigate the potential for statins to increase the expression of the human cathelicidin anti-microbial (CAMP) peptide LL-37/hCAP-18, encoded by the CAMP gene, and explore the underlying mechanisms in various epithelial cell lines of different origins, with special focus on uroepithelial cells. In order to mimic a clinically relevant situation, statin concentrations corresponding to statin plasma levels were used [18, 19] .
Materials and methods

Chemicals
All chemicals, if not indicated otherwise, were obtained from Sigma-Aldrich (St Louis, MO, USA). Simvastatin (S6196) was dissolved in absolute ethanol and then hydrolyzed to the active β-hydroxide acid by addition of 1 M NaOH to a final concentration of 66 mM simvastatin; atorvastatin (PZ0001) was dissolved in dimethylsulphoxide (DMSO) to 100 mM; stock solutions were kept at -20°C for up to 1 month. Mevalonate (M4467) was dissolved in sterile deionized water to a concentration of 100 mM directly before use. Trichostatin A (TSA) was a readymade solution (5 mM in DMSO, T1952). 25-hydroxyvitamin D 3 (vitamin D, Calbiochem; Sigma-Aldrich) was dissolved in absolute ethanol to a concentration of 10 mM. Phenylmethylsulphonyl fluoride (PMSF) solution (0·1 M in ethanol, 93482) and proteinase inhibitor cocktail (P8340) were used according to the manufacturer's recommendation.
Cell lines and culture conditions
Telomerase-immortalized uroepithelial cells (TERTNHUCs), low-passage human epidermal keratinocytes from adult skin (HEKa, C-005-5C; Life Technologies/Thermo Fisher Scientific, Carlsbad, CA, USA), the intestinal epithelial cell line HT-29 originating from a colorectal adenocarcinoma (HTB-38; ATCC, Manassas, VA, USA) and the respiratory cell line A549 originating from alveolar adenocarcinoma (CCL-185; ATCC) were cultured in EpiLife Medium supplemented with human keratinocyte growth supplements (TERT-NHUC and HEKa) or McCoy's 5A modified medium (HT-29) or DMEM medium (A549) supplemented with 10% fetal bovine serum at 37°C and 5% CO 2 in a humidified incubator. TERT-NHUCs were kindly provided by Professor Knowels, University of Leeds, UK; the original samples of normal urothelium were collected following consent from the patient or their guardian and in agreement with the Local Research Ethics Committee [20] . TERT-NHUCs were cultured in Primaria culture dishes (BD Falcon, Bedford, MA, USA), all other cell types were cultured in regular cell culture-treated dishes (Corning, New York, NY, USA or Sarstedt, Nümbrecht, Germany). Cell culture media were from Gibco (Life Technologies).
Cell treatment
For experiments, cells were seeded in multi-well cell culture plates or dishes. Treatment was started when cells were near confluence; HEKa cells were used at 50% confluence, as responsiveness to statins disappeared when cells had reached confluence. Statins and TSA were added at the indicated concentrations in the appropriate cell culture medium and mevalonate and vitamin D were added at a final concentration of 1 mM and 10 nM, respectively. Same volumes of the corresponding vector solutions were added to the control medium. Cells were then incubated for 24 h at 37°C and 5% CO 2 .
Bacteria and cell infection
The pyelonephritis strain Escherichia coli CFT073 was used for cell infection experiments [21] . Bacteria from frozen stock were propagated on blood agar, inoculated into Luria-Bertani medium and incubated overnight at 37°C. This overnight culture was diluted 1 : 100 in fresh LB medium and bacteria were grown to logarithmic phase at 37°C shaking. Bacteria were collected by centrifugation, washed once in phosphate-buffered saline (PBS) and were then adjusted to an optical density of 0·125 at 600 nm, corresponding to 10 8 colony-forming units (CFU)/ml. Bacteria were added to the cells at a multiplicity of infection of 10 bacteria per host cell in fresh medium with appropriate supplements. Infected cells were incubated in a humidified atmosphere at 37°C and 5% CO 2 for 4 h. Supernatant and cells were harvested for further analyses.
Total RNA extraction, cDNA synthesis and gene expression analysis Total RNA was extracted from cells grown in 24 well plates; all conditions were tested in duplicate. The RNeasy Mini Kit (Qiagen, Valencia, CA, USA) was used according to the manufacturer's recommendations. RNA concentrations and purity were determined spectrophotometrically and up to 1 µg RNA was transcribed to cDNA using the high capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). Gene expression was analysed with TaqMan Gene expression assays (Applied Biosystems) for CAMP (Hs00189038_m1), CYP27B1 (Hs01096154_m1) or CXCL8 (Hs00174103_m1) and GAPDH (4326317E) served as internal reference gene. Relative gene expression was calculated as fold change relative to control conditions using the 2 -∆∆CT method.
Anti-microbial killing assay
Cells were cultured in 24 well plates and treated with simvastatin as described above. The anti-bacterial assay was performed as previously described with modifications [22] . After 48 h of treatment, medium was removed and cells were lysed in 1% Triton X-100 in PBS. Lysates were cleared by centrifugation at 8000 g for 5 min and then incubated for 30 min at 37°C with 1 µg/ml of monoclonal mouse anti-LL-37 antibody 3D11 (HM2070, mAb 3D11; HyCult Technologies, Wayne, PA, USA) or the same concentration of an isotype control antibody (553447, mouse immunoglobulin (Ig)G 1 ,κ; BD Biosciences, San Jose, CA, USA). Bacteria were prepared as above and 50 µl of a bacterial suspension with 10 4 CFU/ml was added to 150 µl of pretreated cell lysate. After incubation for 30 min at 37°C, 100 µl aliquots were plated and bacterial survival was determined by viable count. Results were expressed in relation to control cell lysates pretreated with control antibodies.
Infection assay and measurement of interleukin (IL)-8
Cells were grown on 24 well plates, treated for 24 h and infected as described above. To quantify secreted IL-8 in the culture supernatant, medium was collected and cleared from detached cells and bacteria by centrifugation at 300 g and 16 873 g, respectively. Supernatants were stored at -80°C until analysis by enzyme linked immunosorbent assay (ELISA); the human C-X-C motif) ligand 8 (CXCL8)/ IL-8 DuoSet (R&D Systems, Abingdon, UK) was used according to the manufacturer's recommendations. Total mRNA from the cell layer of the same wells was isolated as described above.
Histone acetylation assay
Cells were grown either in 9 cm 2 dishes or cells from two wells of a six-well plate were combined per sample. At the end of the treatment period, cells were washed twice with ice-cold PBS supplemented with 5 mM sodium butyrate and then collected in 1 ml ice-cold Triton extraction buffer (TEB; 0.5% Triton X-100 in PBS) supplemented with PMSF (1 : 100), proteinase inhibitor cocktail (1 : 100) and 10 mM sodium butyrate. The cell lysate was transferred to a 1·5 ml tube and placed on ice for 10 min to complete lysis. Cell nuclei were collected by centrifugation at 6500 g for 10 min at 4°C, the supernatant was discarded and the pellet was washed in 500 µl TEB. Histones were extracted from the pellet by incubation in 0·2 M HCl overnight at 4°C; cell debris was removed by centrifugation. The protein concentration was determined using the BCA assay (Pierce, Thermo Scientific) and samples were stored at -80°C until analysis. An equal amount of protein in 15 µl buffer was mixed with an equal volume of ×2 Tricine sample buffer (Biorad, Hercules, CA, USA) supplemented with 2% β-mercaptoethanol. The pH in the acidic histone extracts was adjusted by adding 1-2 µl ×10 Tris/Tricine/sodium dodecyl sulphate (SDS) running buffer (Biorad). Samples were denaturated at 95°C for 5 min, separated on 10-20% gradient Tris-Tricine polyacrylamide gels (Biorad) and then transferred to PVDF membranes (Invitrogen). Membranes were blocked with 5% milk in Tris-buffered saline with 0·1% Tween 20 and then incubated with primary antibodies overnight at 4°C or for 1 h at room temperature, followed by incubation with horseradish peroxidase (HRP) conjugated anti-rabbit (1 : 30 000; Biorad) or anti-goat (1 : 5000; R&D Systems, Minneapolis, MN, USA) antibodies for 1 h at room temperature. Signals were detected with the SuperSignal West Pico Chemiluminescent kit (Thermo Scientific). Band intensity was quantified using ImageJ software. Blots probed for acetylated histones were stripped and reprobed for total histones as described above. For each experiment, values for acetylated histone were normalized to total histone, then related to results from untreated control cells. Primary antibodies used were goat anti-H3 (1 : 200; sc-8654; Santa Cruz Biotechnologies, Santa Cruz, CA, USA), rabbit anti-H4 (1 : 1,000; ab177840; abcam, Cambridge, MA, USA), rabbit anti-acetyl-H3 (1 : 4000; 06-599; Millipore, Burlington, MA, USA) and rabbit antiacetyl-H4 (1 : 10,000; ab45166; abcam).
Nuclear factor kappa B (NF-κB) translocation
Cells were grown on 9 cm 2 dishes, treated for 24 h and infected as described above. Extraction of the nuclear and cytoplasmic fraction was performed with the NE-PER Nuclear and Cytoplasmic Extraction Reagents following the manufacturer's protocol (Thermo Scientific). Starting material was a cell pellet of approximately 20 µl per sample. The protein concentration in the final extracts was determined using the BCA assay (Pierce, Thermo Scientific) and samples were stored at -80°C until analysis. An equal amount of protein in 15 µl buffer was mixed with an equal volume of 2× Laemmli sample buffer (Biorad) supplemented with 5% β-mercaptoethanol. Samples were denaturated at 95°C for 5 min and then separated on 10% Tris-HCl polyacrylamide gels (Biorad) and transferred to PVDF membranes (Invitrogen). Membranes were blocked in 5% milk in Tris-buffered saline with 0·1% Tween 20 and then incubated with rabbit anti-NF-κB (p65; 1 : 200; sc-372, Santa Cruz Biotechnologies) overnight at 4°C or for 1 h at room temperature, followed by incubation with HRP-conjugated anti-rabbit antibodies (1 : 30 000; Biorad) for 1 h at room temperature. Signals were detected with the SuperSignal West Pico Chemiluminescent kit (Thermo Scientific). Band intensities were quantified using ImageJ software. The degree of nuclear translocation was calculated as the ratio between nuclear and cytosolic NF-κB. For each experiment, results were expressed in relation to control cells.
Detection of LL-37/hCAP-18
Cells were grown on 9 cm 2 dishes and treated for 24 h as described above. Cells were washed with ice-cold PBS, then lysed with ice-cold radioimmunoprecipitation assay (RIPA) buffer supplemented with proteinase inhibitor cocktail (1 : 100). The cells were scraped off the dish, gently transferred to a 1·5 ml tube and maintained at 4°C with constant agitation for 30 min to complete lysis. The cell lysate was centrifuged at 16 873 g for 20 min at 4°C. The supernatant was aspirated, transferred to a new tube and kept on ice. The protein concentration was determined using the BCA assay (Pierce, Thermo Scientific) and samples were stored at -80°C until analysis. An equal amount of protein was mixed with ×4 NuPAGE LDS sample buffer (Invitrogen) to a final ×1 concentration and 10% β-mercaptoethanol. The samples were heated for 10 min at 70°C, then centrifuged at 16 000 g for 10 min. Proteins were separated on a 1·0 mm 4-12% NuPAGE Bis-Tris polyacrylamide gel in NuPAGE MES SDS running buffer (Invitrogen) and transferred to PVDF membranes (Invitrogen). Membranes were cut horizontally for simultaneous detection of β-actin (upper part) and hCAP-18 (lower part). Both membrane parts were blocked with 5% milk in phosphate-buffered saline with 0·1% Tween 20 and then incubated with custom-designed rabbit anti-LL-37 for 1 h at room temperature (1 : 3000; Innovagen, Lund, Sweden) [23] or with rabbit anti-β-actin antibodies (1 : 50 000; #4967L; Cell Signaling Technology, Danvers, MA, USA) overnight at 4°C, respectively, followed by HRP-conjugated anti-rabbit antibodies (1 : 5000; P0448; Dako, Agilent Technologies, Santa Clara, CA, USA) incubation for 1 h at room temperature. Signals were detected with the ECL Western Blotting Detection Reagent (GE Healthcare, Chicago, IL, USA) and visualized by chemiluminescence in the Geldoc XRS+ apparatus (Biorad). Band intensities were quantified using Image Lab software (Biorad). For each experiment, values were first normalized to the loading control (β-actin), then the relative expression of hCAP-18 was expressed in relation to the untreated control cells. Human serum (H4522, lot 113K048 ; Sigma-Aldrich), which naturally contains hCAP-18 (1 µg/ml), was spiked with synthetic LL-37 peptide (0·1 ng/sample) and used as protein standard for both hCAP-18 and LL-37 [24] .
Statistical analysis
All statistical analysis was performed using GraphPad Prism version 6. Data from real-time PCR and ELISA experiments were expected to be normally distributed; statistically confirmed outliers were excluded (Grubb's test). Results were analysed by t-test or with one-or two-way analysis of variance (anova) and Bonferroni's multiple comparison post-test, as appropriate. For analysis of data obtained by Western blot, non-parametric tests were used (Mann-Whitney U-test and Kruskal-Wallis test, respectively). Differences with P < 0·05 were considered statistically significant.
Results
Statins induce CAMP expression in various cell lines
To evaluate the postulated effect of statins on the expression of the anti-microbial peptide LL-37/hCAP-18, we determined the transcription levels of the cathelicidinencoding gene CAMP in response to simvastatin in four different epithelial cell lines originating from the bladder (TERT-NHUC), the gut (HT-29), the lung (A549) and epidermal keratinocytes (HEKa). In bladder epithelial cells and keratinocytes (Fig. 1a,b) , simvastatin at low nanomolar concentrations caused an increase of CAMP transcripts; a similar trend was seen in the intestinal cell line HT-29 (Fig. 1c) . In airway epithelial cells A549, CAMP expression was not influenced by simvastatin (Fig. 1d) . Atorvastatin, another commonly prescribed statin, had similar but less pronounced effects (Supporting information, Fig. S1 ).
Simvastatin affects CAMP expression via different pathways
The classical usage of statins relies on the inhibition of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase activity and thus reduced synthesis of mevalonate, a metabolite in the cholesterol synthesis pathway. To investigate whether statin-mediated CAMP induction was related to HMG-CoA reductase inhibition, mevalonate was added to the experiment. Interestingly, while gene induction by simvastatin was not affected by mevalonate in bladder epithelial cells (Fig. 1a) , complete reversion was seen in HEKa cells (Fig. 1b) ; mevalonate appeared to have a similar effect in HT-29 intestinal epithelial cells (Fig. 1c) .
In addition to this classical function of statins, these drugs have been suggested to exert inhibitory actions on histone deacetylases (HDAC) [25] . We used a well-known HDAC inhibitor, trichostatin A (TSA) to examine the effect of HDAC inhibition on CAMP expression in the different cell lines (Fig. 2a) . In bladder epithelial cells, TSA clearly induced CAMP expression in a concentrationdependent manner, and a similar trend was observed in HT-29. In contrast, TSA did not induce CAMP in HEKa or A549 cells. We thus hypothesized that HDAC inhibition might be responsible for statin-mediated CAMP induction in bladder, while statin-mediated induction of CAMP transcription was mevalonate-dependent but independent on histone acetylation in HEKa cells. The expression patterns observed in HT-29 suggested a mixed mechanism. 
Simvastatin enhances acetylation of histones
To further explore this hypothesis, we analysed the histone acetylation status in TERT-NHUCs treated with simvastatin for 24 h. Acetylation of histone 3 (H3) was elevated in relation to total H3 in the presence of simvastatin (Fig. 2b) , while histone 4 (H4) was not affected (data not shown). Interestingly, atorvastatin, which was weaker in its capacity to induce CAMP expression, had no impact on H3 acetylation in these cells under the conditions investigated here (data not shown). Also, in HEKa cells, in which CAMP induction was clearly reversible by mevalonate (Fig. 1b) and TSA had no effect (Fig. 2a) , an increase on histone acetylation by simvastatin could not be noted (data not shown).
Simvastatin induces anti-bacterial activity
To investigate whether the simvastatin-induced increased expression of CAMP was translated into a biological effect, we tested the anti-bacterial activity of simvastatintreated TERT-NHUCs. Survival of E. coli exposed to lysates from simvastatin-treated cells was significantly reduced compared to lysates from control cells (Fig. 3) . Cell lysates were incubated with LL-37-specific monoclonal antibodies (α-LL-37) or isotype control antibodies (α-X) before Escherichia coli CFT073 was added. After incubation for 30 min, bacterial survival was determined by viability count. Results are expressed in relation to control cells (0 nM, α-X). Data from five independent experiments are shown as mean and standard error of the mean (s.e.m.); results were analysed with two-way analysis of variance (anova) with Bonferroni's multiple comparison post-test; *P < 0·05, **P < 0·01, ****P < 0·0001 versus the corresponding control (0 nM) or as indicated. A specific monoclonal antibody directed against the active peptide LL-37 resulted in higher bacterial numbers, demonstrating that the increased anti-microbial activity was mediated by this peptide. The LL-37-specific antibody had no effect on bacterial survival in lysates from control cells.
Statins induce expression of the vitamin D-activating enzyme CYP27B1
A linkage between statins and vitamin D levels has long been suggested, although clinical data on this association are conflicting [26, 27] . However, experimental data were treated with simvastatin for 24 h in the absence (plain bars) or presence of mevalonate (hatched bars). Transcription levels of CXCL8 were determined by reverse transcription real-time polymerase chain reaction (PCR) and are expressed in relation to control cells (0 nM) with or without mevalonate, respectively (a); results of three to six independent experiments were analysed by two-way analysis of variance (anova) with Bonferroni's multiple comparison post-test; *P < 0·05, **P < 0·01 versus control cells (0 nM). Secreted interleukin (IL)-8 was measured by enzymelinked immunosorbent assay (ELISA) and is expressed in relation to levels from control cells (b); results from three independent experiments were compared by unpaired two-tailed t-test. Cells were treated as in (a) and then infected with Escherichia coli CFT073 for 4 h. The cytoplasmic (c) and nuclear (n) protein fractions were extracted and analysed by Western blot (c). Nuclear factor kappa B (NF-κB) was quantified densitometrically; results from three to five independent experiments are expressed as nuclear-to-cytoplasmic ratio of NF-κB subunit p65 and were analysed by Mann-Whitney U-test; *P < 0·05 versus non-infected cells (empty bars). Expression of CXCL8 and IL-8 secretion was determined by reverse transcription real-time PCR and ELISA (d); levels are expressed versus correspondingly treated, non-infected cells (=1). Data from three independent experiments are shown as mean and standard error of the mean (s.e.m.); analyses were performed using two-way (anova).
demonstrate that statins can elevate circulating vitamin D levels by induction of vitamin D-activating enzymes [28] . As vitamin D is a well-known inducer of LL-37/ hCAP-18 [29] , we sought to investigate whether statins also had an effect on the vitamin D-activating enzyme CYP27B1 in epithelial cells. Indeed, simvastatin induced CYP27B1 transcription in TERT-NHUCs (Fig. 4a) , and a combined treatment of vitamin D and simvastatin resulted in higher induction of CAMP transcription and hCAP18 protein expression than did the two substances separately (Fig. 4b,c) .
Simvastatin reduces CXCL8 transcription
The previously reported anti-inflammatory actions of statins have been related mainly to the mevalonate pathway [30] [31] [32] [33] . As simvastatin's effect in TERT-NHUCs was clearly independent of mevalonate, we sought to characterize the anti-inflammatory effect of statins in these cells. Simvastatin, but not atorvastatin, reduced levels of CXCL8-specific mRNA, as determined after a 24 h treatment (Fig. 5a,  Supporting information, Fig. S2) ; like CAMP induction, the effect on CXCL8-transcription was independent of mevalonate. The inhibitory effect of simvastatin on CXCL8 expression was also mirrored by a slight non-significant reduction of IL-8 protein secretion at baseline (Fig. 5b) . To further explore the underlying mechanisms of this effect, we investigated the cellular distribution of NF-κB subunit p65 in cells treated with simvastatin. While the total amount of subunit p65 was not significantly affected, the nuclearto-cytoplasmic ratio of p65 was decreased upon simvastatin treatment at baseline (Fig. 5c) , indicating reduced activation of NF-κB dependent genes in simvastatin-treated cells. However, in the presence of bacteria, simvastatin did not inhibit translocation of p65 into the nucleus and consequently induction of IL-8 was not inhibited, neither on mRNA nor on protein level (Fig. 5d) .
Discussion
The pleiotropic effects of the cholesterol-lowering drugs statins on the immune system are well accepted, although the underlying mechanisms are not fully understood. Here we investigated the effect of statins on epithelial expression of the anti-microbial peptide LL-37/hCAP-18. We show that simvastatin induces CAMP mRNA and hCAP-18 protein in epithelial cells from the urinary bladder and CAMP mRNA in the gastrointestinal tract and in skin keratinocytes, but no response could be detected in airway epithelial cells A549. Moreover, our data indicate that statins exert this effect via different pathways in different types of cells.
Differences in the regulation of CAMP expression, dependent on cellular origin, transformation [34] and differentiation [35] as well as environmental conditions [36] , have been suggested previously. A cell-specific methylation pattern of the CAMP gene promoter region and gene expression has recently been demonstrated [37] , adding to the possible mechanisms by which tissue-specific regulation of the CAMP gene may occur.
Apart from their classical function to inhibit HMGCoA reductase activity, statins have been reported to exhibit inhibitory actions on histone deacetylases (HDAC), directly [25] or indirectly , by down-regulation of HDAC gene expression [38] . Together with histone acetyltransferases, HDACs modify the net acetylation status of histones, thereby influencing the accessibility to the promotor or other enhancer elements in the genome [39] . Inhibition of HDACs is thus generally associated with enhanced gene transcription.
Induction of the anti-microbial peptide LL-37/hCAP-18 by HDAC inhibition is well recognized. Several studies have investigated the effect of butyrate in gastrointestinal cells [34, 40, 41] and on the gut [42] . Our results using the intestinal cell line HT-29 and the synthetic HDAC inhibitor TSA agree with these previous reports. However, induction of CAMP gene expression by simvastatin appeared to depend at least partly on mevalonate-dependent mechanisms in these cells. Simvastatin-mediated CAMP gene induction in keratinocytes was solely related to a mevalonate-dependent mechanism, and HDAC inhibition, in line with previous reports [43] , did not induce CAMP expression. Both HDAC inhibitors [44] as well as simvastatin [10] have been reported to induce CAMP gene expression in epithelial cells from the respiratory tract. In contrast, neither simvastatin nor TSA increased expression of LL-37/hCAP-18 in A549 cells investigated in our study. Statt et al. observed a mevalonate-dependent induction of CAMP gene expression by simvastatin in airway epithelial cells [10] . However, this effect was demonstrated at a concentration of 1 µM simvastatin, while we applied concentrations in the nanomolar range as these are concentrations obtained in serum from patients receiving statin therapy [45] . In addition, the effect was more pronounced in primary epithelial cells compared to the virus-immortalized cell line in that study. Interestingly, Liu et al. also used a respiratory cell line which had retained its mucoepidermoid characteristics [44] . Thus, we propose that discrepancies in the results may partly relate to the high degree of transformation of cell line A549 in comparison to cells used in the studies mentioned above.
We have previously observed that butyrate induces LL-37/hCAP-18 peptide in an epithelial cell line originating from the urinary bladder [46] . Results from the present study confirm that HDAC inhibition increases expression of the CAMP gene and suggest that simvastatin-mediated CAMP induction is also based on this mechanism.
Several vitamin D-responsive elements are located in the CAMP gene promotor region, whereby vitamin D is a strong inducer of LL-37/hCAP-18 expression [47, 48] . Conversely, statins have been suggested to influence vitamin D metabolism or signalling [49] [50] [51] [52] . Similar to effects obtained with lovastatin in neuronal tissue in vivo [28] , we observed that simvastatin induced expression of the vitamin D-activating enzyme CYP27B1 in bladder epithelial cells. We have previously demonstrated that these cells are able to activate vitamin D locally [22] , and therefore investigated whether vitamin D and simvastatin might have a synergistic effect on LL-37/hCAP-18 expression. However, even though we noted higher levels of the hCAP18 protein when both substances were added together, a synergistic effect was not statistically evident. This might be due to tight regulation of CAMP transcription and propeptide production, preventing over-production of the potentially cytotoxic peptide LL-37 in the absence of inflammatory stimuli.
The anti-inflammatory activity of statins has been reported repeatedly [2] , both in clinical studies and experimentally [30] [31] [32] . The underlying mechanisms are, however, less clear. As NF-κB signalling is an early and essential step in the induction of IL-8 production [53] , and reduced NF-κB signalling by statins has previously been reported [30, 54, 55] , we focused our investigations on this pathway. In contrast to Chen et al., our data do not suggest reduced stability of NF-κB in the presence of statins [54] , but rather that statins influenced cellular distribution, i.e. diminished the recruitment of the p65 subunit to the nucleus. This has previously been related to the increased stability of IκB in the presence of simvastatin, consequently limiting recruitment of cytosolic NF-κB to the nucleus [56] . In contrast to studies by others, effects of statins observed in bladder epithelial cells TERT-NHUC were independent of mevalonate. A possible explanation might be, again, that higher concentration of statins in the micromolar range were investigated [30, [54] [55] [56] , while we used concentrations in the nanomolar range for our experiments.
Clinical studies suggest reduced mortality in statintreated patients suffering from severe infectious diseases, including sepsis [57] [58] [59] [60] . However, meta-analyses of randomized trials question the benefit of statins in this context [61] [62] [63] [64] . We show here that statins are able to promote expression of the human CAMP LL-37/hCAP-18 in epithelial cells, with a significant anti-bacterial effect in bladder epithelial cells. These results indicate that boosting with simvastatin might be one possible treatment avenue to explore further in patients with recurrent infections in the urinary bladder. Contrasting results in different cell types investigated in the present study indicate organspecific reactions and suggest that statins may impact disease conditions differently, possibly explaining inconsistent results in clinical studies. To demonstrate the functional consequences of the molecular effects in vivo, complementing studies are needed.
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